EGFR and non-small cell lung carcinoma: As a result of intrinsic resistance, 20-30% of NSCLC patients with activating EGFR mutations do not respond to the treatment with EGFR-TK inhibitors and almost all patients with an initial positive response eventually develop acquired resistance within a relatively short time of treatment 6.